AMTI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AMTI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Applied Molecular Transport's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $16.24 Mil. Applied Molecular Transport's Total Assets for the quarter that ended in Sep. 2023 was $20.02 Mil.
The historical rank and industry rank for Applied Molecular Transport's Equity-to-Asset or its related term are showing as below:
During the past 5 years, the highest Equity to Asset Ratio of Applied Molecular Transport was 0.96. The lowest was -1.90. And the median was 0.76.
The historical data trend for Applied Molecular Transport's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Applied Molecular Transport Annual Data | |||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | ||||||
Equity-to-Asset | -1.90 | -1.86 | 0.94 | 0.76 | 0.57 |
Applied Molecular Transport Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.63 | 0.57 | 0.43 | 0.83 | 0.81 |
For the Biotechnology subindustry, Applied Molecular Transport's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Applied Molecular Transport's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Applied Molecular Transport's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Applied Molecular Transport's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as
Equity to Asset (A: Dec. 2022 ) | = | Total Stockholders Equity | / | Total Assets |
= | 60.838 | / | 107.446 | |
= |
Applied Molecular Transport's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as
Equity to Asset (Q: Sep. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 16.24 | / | 20.015 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Applied Molecular Transport (NAS:AMTI) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Applied Molecular Transport's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Shawn Cross | officer: Chief Financial Officer | 1825 K STREET SUITE 510, WASHINGTON DC 20006 |
Mahmood Tahir Ph.d. | director, officer: Chief Executive Officer | 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080 |
Brandon Hants | officer: VP, Finance & Bus. Ops. | 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080 |
Douglas A. Rich | officer: Chief Technical Officer | C/O KYTHERA BIOPHARMACEUTICALS, INC., 30930 RUSSELL RANCH ROAD, 3RD FLOOR, WESTLAKE VILLAGE CA 91362 |
Bittoo Kanwar | officer: Chief Medical Officer | 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080 |
Mrsny Randall Ph.d. | director, officer: Chief Scientific Officer | 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080 |
Aaron Vandevender | director | 1 TOWER PLACE, SUITE 850, SOUTH SAN FRANCISCO CA 94080 |
David Lamond | director | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Epiq Capital Group, Llc | other: Managing member of 10% owner | ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111 |
Chad Boeding | other: CEO of Managing Member | ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111 |
Charlene A. Banard | director | C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080 |
John W Smither | director | C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301 |
Epq Llc Amt Ps | other: Owner | 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521 |
Epq Llc, Amtc Ps | other: Owner | 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521 |
Epq Llc, Amtb Ps | 10 percent owner | 9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521 |
From GuruFocus
By Marketwired • 08-14-2023
By GuruFocusNews GuruFocusNews • 07-08-2022
By Tiesvg Tiesvg • 12-22-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By Value_Insider Value_Insider • 11-08-2022
By PurpleRose PurpleRose • 08-02-2022
By PurpleRose PurpleRose • 07-15-2022
By sperokesalga sperokesalga • 03-27-2023
By PurpleRose PurpleRose • 07-15-2022
By PRNewswire • 09-22-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.